1
|
Pane R, Laib L, Formoso K, Détrait M, Sainte-Marie Y, Bourgailh F, Ruffenach N, Faugeras H, Simon I, Lhuillier E, Lezoualc'h F, Conte C. Macromolecular Complex Including MLL3, Carabin and Calcineurin Regulates Cardiac Remodeling. Circ Res 2024; 134:100-113. [PMID: 38084599 DOI: 10.1161/circresaha.123.323458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2023] [Accepted: 11/27/2023] [Indexed: 01/06/2024]
Abstract
BACKGROUND Cardiac hypertrophy is an intermediate stage in the development of heart failure. The structural and functional processes occurring in cardiac hypertrophy include extensive gene reprogramming, which is dependent on epigenetic regulation and chromatin remodeling. However, the chromatin remodelers and their regulatory functions involved in the pathogenesis of cardiac hypertrophy are not well characterized. METHODS Protein interaction was determined by immunoprecipitation assay in primary cardiomyocytes and mouse cardiac samples subjected or not to transverse aortic constriction for 1 week. Chromatin immunoprecipitation and DNA sequencing (ChIP-seq) experiments were performed on the chromatin of adult mouse cardiomyocytes. RESULTS We report that the calcium-activated protein phosphatase CaN (calcineurin), its endogenous inhibitory protein carabin, the STK24 (STE20-like protein kinase 3), and the histone monomethyltransferase, MLL3 (mixed lineage leukemia 3) form altogether a macromolecular complex at the chromatin of cardiomyocytes. Under basal conditions, carabin prevents CaN activation while the serine/threonine kinase STK24 maintains MLL3 inactive via phosphorylation. After 1 week of transverse aortic constriction, both carabin and STK24 are released from the CaN-MLL3 complex leading to the activation of CaN, dephosphorylation of MLL3, and in turn, histone H3 lysine 4 monomethylation. Selective cardiac MLL3 knockdown mitigates hypertrophy, and chromatin immunoprecipitation and DNA sequencing analysis demonstrates that MLL3 is de novo recruited at the transcriptional start site of genes implicated in cardiomyopathy in stress conditions. We also show that CaN and MLL3 colocalize at chromatin and that CaN activates MLL3 histone methyl transferase activity at distal intergenic regions under hypertrophic conditions. CONCLUSIONS Our study reveals an unsuspected epigenetic mechanism of CaN that directly regulates MLL3 histone methyl transferase activity to promote cardiac remodeling.
Collapse
Affiliation(s)
- Roberto Pane
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Loubna Laib
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Karina Formoso
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Maximin Détrait
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Yannis Sainte-Marie
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Florence Bourgailh
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Nolan Ruffenach
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Hanamée Faugeras
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Ilias Simon
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Emeline Lhuillier
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
- GeT-Sante, Plateforme Genome et Transcriptome, GenoToul, Toulouse, France (E.L.)
| | - Frank Lezoualc'h
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| | - Caroline Conte
- Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Université de Toulouse III-Paul Sabatier, France (R.P., L.L., K.F., M.D.., Y.S.-M., F.B., N.R., H.F., I.S., E.L., F.L., C.C.)
| |
Collapse
|
2
|
Santin Y, Formoso K, Haidar F, Fuentes MDPO, Bourgailh F, Hifdi N, Hnia K, Doghri Y, Resta J, Champigny C, Lechevallier S, Détrait M, Cousin G, Bisserier M, Parini A, Lezoualc'h F, Verelst M, Mialet-Perez J. Inhalation of acidic nanoparticles prevents doxorubicin cardiotoxicity through improvement of lysosomal function. Theranostics 2023; 13:5435-5451. [PMID: 37908733 PMCID: PMC10614672 DOI: 10.7150/thno.86310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Accepted: 08/04/2023] [Indexed: 11/02/2023] Open
Abstract
Doxorubicin (Dox) is an effective anticancer molecule, but its clinical efficacy is limited by strong cardiotoxic side effects. Lysosomal dysfunction has recently been proposed as a new mechanism of Dox-induced cardiomyopathy. However, to date, there is a paucity of therapeutic approaches capable of restoring lysosomal acidification and function in the heart. Methods: We designed novel poly(lactic-co-glycolic acid) (PLGA)-grafted silica nanoparticles (NPs) and investigated their therapeutic potential in the primary prevention of Dox cardiotoxicity in cardiomyocytes and mice. Results: We showed that NPs-PLGA internalized rapidly in cardiomyocytes and accumulated inside the lysosomes. Mechanistically, NPs-PLGA restored lysosomal acidification in the presence of doxorubicin or bafilomycin A1, thereby improving lysosomal function and autophagic flux. Importantly, NPs-PLGA mitigated Dox-related mitochondrial dysfunction and oxidative stress, two main mechanisms of cardiotoxicity. In vivo, inhalation of NPs-PLGA led to effective and rapid targeting of the myocardium, which prevented Dox-induced adverse remodeling and cardiac dysfunction in mice. Conclusion: Our findings demonstrate a pivotal role for lysosomal dysfunction in Dox-induced cardiomyopathy and highlight for the first time that pulmonary-driven NPs-PLGA administration is a promising strategy against anthracycline cardiotoxicity.
Collapse
Affiliation(s)
- Yohan Santin
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Karina Formoso
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Fraha Haidar
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Maria Del Pilar Oreja Fuentes
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Florence Bourgailh
- Center for Electron Microscopy Applied to Biology (CMEAB), Université de Toulouse, Faculté de Médecine, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Nesrine Hifdi
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Karim Hnia
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Yosra Doghri
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Jessica Resta
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Camille Champigny
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Séverine Lechevallier
- Center for Materials Development and Structural Studies (CEMES), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Maximin Détrait
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Grégoire Cousin
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
| | - Malik Bisserier
- New York Medical College, New York, Department of Cell Biology and Anatomy, and of Physiology, Valhalla, New York, United States
| | - Angelo Parini
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Frank Lezoualc'h
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Marc Verelst
- Center for Materials Development and Structural Studies (CEMES), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Jeanne Mialet-Perez
- Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| |
Collapse
|
3
|
Record M, Attia M, Carayon K, Pucheu L, Bunay J, Soulès R, Ayadi S, Payré B, Perrin‐Cocon L, Bourgailh F, Lamazière A, Lotteau V, Poirot M, Silvente‐Poirot S, de Medina P. Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome-enriched vesicles. J Extracell Vesicles 2022; 11:e12211. [PMID: 35411723 PMCID: PMC9001168 DOI: 10.1002/jev2.12211] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 03/07/2022] [Accepted: 03/21/2022] [Indexed: 01/02/2023] Open
Abstract
Tumour cells are characterized by having lost their differentiation state. They constitutively secrete small extracellular vesicles (sEV) called exosomes when they come from late endosomes. Dendrogenin A (DDA) is an endogenous tumour suppressor cholesterol‐derived metabolite. It is a new class of ligand of the nuclear Liver X receptors (LXR) which regulate cholesterol homeostasis and immunity. We hypothesized that DDA, which induces tumour cell differentiation, inhibition of tumour growth and immune cell infiltration into tumours, could functionally modify sEV secreted by tumour cells. Here, we have shown that DDA differentiates tumour cells by acting on the LXRβ. This results in an increased production of sEV (DDA‐sEV) which includes exosomes. The DDA‐sEV secreted from DDA‐treated cells were characterized for their content and activity in comparison to sEV secreted from control cells (C‐sEV). DDA‐sEV were enriched, relatively to C‐sEV, in several proteins and lipids such as differentiation antigens, “eat‐me” signals, lipidated LC3 and the endosomal phospholipid bis(monoacylglycero)phosphate, which stimulates dendritic cell maturation and a Th1 T lymphocyte polarization. Moreover, DDA‐sEV inhibited the growth of tumours implanted into immunocompetent mice compared to control conditions. This study reveals a pharmacological control through a nuclear receptor of exosome‐enriched tumour sEV secretion, composition and immune function. Targeting the LXR may be a novel way to reprogram tumour cells and sEV to stimulate immunity against cancer.
Collapse
Affiliation(s)
- Michel Record
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Mehdi Attia
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Kevin Carayon
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Laly Pucheu
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Julio Bunay
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Régis Soulès
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Silia Ayadi
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Bruno Payré
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Laure Perrin‐Cocon
- Team “ VIRal InfectionMetabolism and ImmunityCIRICentre International de Recherche en InfectiologieUniv LyonInsermU1111Université Claude Bernard Lyon 1CNRSUMR5308ENS de LyonLyonFrance
| | - Florence Bourgailh
- Centre de Microscopie Electronique Appliquée à la BiologieFaculté de Médecine RangueilToulouseFrance
| | - Antonin Lamazière
- Sorbonne UniversitéINSERMCentre de Recherche Saint‐AntoineCRSAAP‐HP.SUHôpital Saint AntoineDépartement de métabobolomique cliniqueParisFrance
| | - Vincent Lotteau
- Team “ VIRal InfectionMetabolism and ImmunityCIRICentre International de Recherche en InfectiologieUniv LyonInsermU1111Université Claude Bernard Lyon 1CNRSUMR5308ENS de LyonLyonFrance
| | - Marc Poirot
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Sandrine Silvente‐Poirot
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| | - Philippe de Medina
- Team “Cholesterol Metabolism and Therapeutic Innovations” Cancer Research Centre of Toulouse (CRCT)UMR 1037 INSERMUMR 5071 CNRSUniversité de Toulouse IIIEquipe labellisée par la Ligue Nationale Contre le CancerFrench network for Nutrition And Cancer Research (NACRe network)France
| |
Collapse
|